Adverse cutaneous effects of neratinib

Hamid, Ramiz N; Ahn, Christine S.; Huang, William W.

doi:10.1080/09546634.2018.1536253

Cited by 8 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can also have rare related cutaneous side effects, which is similar to the EGFR inhibitors. 71 In the salvage treatment, the combination therapy with neratinib proved to be more efficient than lapatinib and well-tolerated. 21,22,72 In a phase II trial, designers evaluated the efficacy of neratinib plus capecitabine in 68 eligible HER2positive mBC patients pretreated with trastuzumab as well as lapatinib.…”

Section: Neratinibmentioning

confidence: 99%

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer

Yang

Yuan

2020

Technol Cancer Res Treat

View full text Add to dashboard Cite

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) accounts for about 20% to 30% of all BC subtypes and is characterized by invasive disease and poor prognosis. With the emergence of anti-HER2 target drugs, HER2-positive BC patient outcomes have changed dramatically. However, treatment failure is mostly due to drug resistance and the special treatment needs of different subgroups. Small molecule tyrosine kinase inhibitors can inhibit multiple targets of the human epidermal growth factor receptor family and activate PI3K/AKT, MAPK, PLC γ, ERK1/2, JAK/STAT, and other pathways affecting the expression of MDM2, mTOR, p27, and other transcription factors. This can help regulate the differentiation, apoptosis, migration, growth, and adhesion of normal cells and reverse drug resistance to a certain extent. These inhibitors can cross the blood-brain barrier and be administered orally. They have a good synergistic effect with effective drugs such as trastuzumab, pertuzumab, t-dm1, and cyclin-dependent kinase 4 and 6 inhibitors. These advantages have resulted in small-molecule tyrosine kinase inhibitors attracting attention. The new small-molecule tyrosine kinase inhibitor was investigated in multi-target anti-HER2 therapy, showed a good effect in preclinical and clinical trials, and to some extent, improved the prognosis of HER2-positive BC patients. Its use could lead to a de-escalation of treatment in some patients, possibly preventing unnecessary procedures along with the associated side effects and costs.

show abstract

Section: Neratinibmentioning

confidence: 99%

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer

Yang

Yuan

2020

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…The most frequently reported adverse effect is diarrhea, and certain clinicians advise initiating anti-diarrheal prophylaxis with the initial dose. 21 Nausea, diarrhea, and fatigue were the three most frequently associated adverse effects with tucatinib. 22 Hence, it is urgent to develop drugs that demonstrate competent efficacy and reduced toxicity.…”

Section: Introductionmentioning

confidence: 99%